Dicerna Pharmaceuticals reported $-40269000 in Pre-Tax Profit for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acceleron Pharma XLRN:US $ -63.51M 0.05M
Agenus AGEN:US $ -83.99M 29.59M
Alnylam Pharmaceuticals ALNY:US $ -188.33M 10.94M
Arrowhead Research ARWR:US $ -29.92M 3.11M
Bluebird Bio BLUE:US $ -231.42M 25.67M
Dicerna Pharmaceuticals DRNA:US $ -40.27M 10.3M
Exelixis EXEL:US $ 124.89M 126.9M
GlaxoSmithKline GSK:LN 1482M 225M
Immunogen IMGN:US $ -30.74M 3.31M
Intercept Pharmaceuticals ICPT:US $ -11.09M 29.33M
Intrexon XON:US $ -20.12M 1.77M
IONIS PHARMACEUT IONS:US $ -81M 8.74M
Karyopharm Therapeutics KPTI:US $ -53448000 3.82M
Macrogenics MGNX:US $ -39.94M 11.34M
Regeneron Pharmaceuticals REGN:US $ 3898.3M 2658.7M
Regulus Therapeutics RGLS:US $ -6.03M 0.02M
Ultragenyx Pharmaceutical RARE:US $ -121.96M 13.8M